Overview

Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer

Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
0
Participant gender:
All
Summary
This Phase II study is to determine the efficacy of split-course irradiation with concurrent chemotherapy in locally advanced none-small cell lung cancer patients.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Docetaxel
Nedaplatin
Criteria
Inclusion Criteria:

- Pathologic confirmation of NSCLC.

- Patients have measurable or evaluable lesions based on the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria.

- Unresectable phase IIIA(N2) and IIIB lung cancer confirmed by PET/CT, CT or MRI.

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

- Previously treated with chemotherapy or treatment-naive

- No previous chest radiotherapy, immunotherapy or biotherapy

- Hemoglobin≥10 mg/dL, platelet≥100000/μL,absolute neutrophil count ≥1500/μL

- Serum creatinine ≤1.25 times the upper normal limit(UNL), or creatinine clearance≥60
ml/min

- Bilirubin ≤1.5 times UNL, AST(SGOT)≤2.5 times UNL ,ALT(SGPT)≤2.5 times UNL,alkaline
phosphatase ≤5 times UNL

- FEV1 >0.8 L

- CB6 within normal limits

- patients and their family signed the informed consents

Exclusion Criteria:

- Previous or recent another malignancy, except nonmelanoma skin cancer or cervical
cancer in situ

- Contraindication for chemotherapy

- Malignant pleural or pericardial effusion.

- Women in pregnancy, lactation period, or no pregnancy test 14 days before the first
dose

- Women who has the probability of pregnancy without contraception

- Tendency of hemorrhage

- In other clinical trials within 30 days

- Addicted in drugs or alcohol, AIDS patients

- Uncontrollable seizure or psychotic patients without self-control ability

- Severe allergy or idiosyncrasy

- Not suitable for this study judged by researchers